Jupiter Life Line Hospitals Limited has informed the Exchange about Investor Presentation
JLHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jupiter Life Line Hospitals reported FY25 total income of Rs 1,261.5 cr (+17.5% YoY), EBITDA of Rs 296.6 cr (+22.5% YoY), and PAT of Rs 193.5 cr (+9.6% YoY). EBITDA margin expanded to 23.5% from 22.6%, supported by ARPOB rising 10.4% to Rs 60,600 and occupancy improving to 65.3% from 63.8%. Operational bed capacity grew to 1,061 (from 961), with IPD and OPD volumes also up. The company laid out a clear expansion pipeline to 2,494 beds across Western India, including a 500-bed Dombivli hospital (Q1FY27), a 500-bed Pune II hospital, and a 300-bed Mira-Bhayandar hospital. Net cash at the standalone entity stands at Rs 527 cr, with phase 1 capex estimated at Rs 572-632 cr.
Strong margin expansion, robust cash generation, and a well-defined multi-year bed addition roadmap through CY29 are positives for the stock. The low leverage at the listed entity and visible growth pipeline should support investor confidence, though execution of three new hospital projects remains a key thing to watch.